Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
Phyllis Foxworth discusses how clinicians and patients can work together to more closely align their goals and outcomes when treating mood disorders, and explores realistic expectations for treatment and tips for family and friends of...
Phyllis Foxworth discusses how clinicians and patients can work together to more closely align their goals and outcomes when treating mood disorders, and explores realistic expectations for treatment and tips for family and friends of...
Phyllis Foxworth addresses how the COVID-19 pandemic has exacerbated feelings of isolation in patients with bipolar 1 disorder (BD-I) and tools for clinicians who are treating these patients.
Phyllis Foxworth addresses how the COVID-19 pandemic has exacerbated feelings of isolation in patients with bipolar 1 disorder (BD-I) and tools for clinicians who are treating these patients.
Craig Chepke, MD, FAPA, shares his key insights and takeaways regarding the burden on people living with bipolar I disorder, especially as it relates to the importance of person-centered care.
Craig Chepke, MD, FAPA, shares his key insights and takeaways regarding the burden on people living with bipolar I disorder, especially as it relates to the importance of person-centered care.
Craig Chepke, MD, FAPA, discusses the impact of COVID-19 and the burden on people living with bipolar I disorder, specifically the important topics of isolation, medication trial and error, and stigma.
Craig Chepke, MD, FAPA, discusses the impact of COVID-19 and the burden on people living with bipolar I disorder, specifically the important topics of isolation, medication trial and error, and stigma.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the utility and limitations of pharmacogenetics in the treatment of bipolar disorders.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the utility and limitations of pharmacogenetics in the treatment of bipolar disorders.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the concept of polarity-proneness and why clinicians should assess it when treating patients with bipolar disorder.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the concept of polarity-proneness and why clinicians should assess it when treating patients with bipolar disorder.
Jessica Whelan, DNP, APRN, FPMHNP-BC reviews the many factors that come in to play when she is developing a treatment plan for her patients with bipolar disorder.
Jessica Whelan, DNP, APRN, FPMHNP-BC reviews the many factors that come in to play when she is developing a treatment plan for her patients with bipolar disorder.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains some key distinctions between bipolar I disorder and bipolar II disorder and treatment implications of the differences.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains some key distinctions between bipolar I disorder and bipolar II disorder and treatment implications of the differences.
Jessica Whelan, DNP, APRN, FPMHNP-BC discusses the value of understanding the neurobiology behind bipolar disorder and how she explains it to her patients.
Jessica Whelan, DNP, APRN, FPMHNP-BC discusses the value of understanding the neurobiology behind bipolar disorder and how she explains it to her patients.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Watch these exclusive insights with Desiree Matthews, PMHNP-BC, to learn how this novel treatment could reshape the landscape of care for adults living with schizophrenia.
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Dr Marc Agronin discusses some easy prevention strategies for Alzheimer disease following his Psych Congress 2024 session "A New Era for Alzheimer’s Disease: Prevention, Early Diagnosis, Effective Intervention."
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
Although the diagnostic criteria for the two conditions seem distinctive at first glance, there is a significant degree of variability of symptom presentation.
Although the diagnostic criteria for the two conditions seem distinctive at first glance, there is a significant degree of variability of symptom presentation.
Help me to let go and Live, to bloom in resonance with the rest of our passionate universe. To see my own life as something sacred and not just a death sentence to serve until it is finally over.
Help me to let go and Live, to bloom in resonance with the rest of our passionate universe. To see my own life as something sacred and not just a death sentence to serve until it is finally over.
To truly recover, the questions surrounding survival become more basic, more fundamental, and less focused on a particular disorder. They become more about life.
To truly recover, the questions surrounding survival become more basic, more fundamental, and less focused on a particular disorder. They become more about life.
The foundational piece in each part of my journey today has been my relationship with my treatment team. When treating a client, it is important to remember that you may be the only close relationship they have or can trust.
The foundational piece in each part of my journey today has been my relationship with my treatment team. When treating a client, it is important to remember that you may be the only close relationship they have or can trust.
Years after my time in the VA hospital, I had been asked to present back at the hospital in which I was once a patient. In the back row was an MD who seemed to be on the brink of tears. This was the doctor I thought was trying to kill me when...
Years after my time in the VA hospital, I had been asked to present back at the hospital in which I was once a patient. In the back row was an MD who seemed to be on the brink of tears. This was the doctor I thought was trying to kill me when...
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...
Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp):
An upstream solution to Mental Health(MH) access issues within the VA system
Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...
In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...
The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
It is...
How to Use
Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
It is...
How to Use
The Bipolar Spectrum Diagnostic Scale (BSDS) is a descriptive story that captures subtle features of bipolar illness. It does not provide a “yes” or “no” answer to whether or not a patient has bipolar disorder – it addresses the...
How to Use
The Bipolar Spectrum Diagnostic Scale (BSDS) is a descriptive story that captures subtle features of bipolar illness. It does not provide a “yes” or “no” answer to whether or not a patient has bipolar disorder – it addresses the...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.